Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO-202 +/- Azacitidine +/- Venetoclax in AML and CMML
NCT04372433Phase 1Completed
- Sponsor
- Immune-Onc Therapeutics
- Start
- Sep 2020
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IO-202 in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (5 arms), sponsored by Immune-Onc Therapeutics. Primary endpoints: Incidence of Adverse Events and Incidence and duration of dose interruptions and reductions. Started Sep 2020; status: completed.
02
Drugs
IO-202
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04372433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372433.